Editorial

You have full text access to this OnlineOpen article

Good and bad memories following rituximab therapy

  1. E. William St.Clair†,*

Article first published online: 28 DEC 2009

DOI: 10.1002/art.25039

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 62, Issue 1, pages 1–5, January 2010

Additional Information

How to Cite

St.Clair, E. W. (2010), Good and bad memories following rituximab therapy. Arthritis & Rheumatism, 62: 1–5. doi: 10.1002/art.25039

Author Information

  1. Duke University Medical Center, Durham, North Carolina

  1. †

    Dr. St.Clair has received consulting fees, speaking fees, and/or honoraria from Biogen Idec (less than $10,000).

*Box 3874 Duke University Medical Center, Durham, NC 27710

Publication History

  1. Issue published online: 28 DEC 2009
  2. Article first published online: 28 DEC 2009
  3. Manuscript Accepted: 8 SEP 2009
  4. Manuscript Received: 7 JUL 2009

Funded by

  • NIH. Grant Numbers: AI-056363, AI-15416
  • Genentech

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (58K)

REFERENCES

  • 1
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613–20.
    Direct Link:
  • 2
    Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64–74.
    Direct Link:
  • 3
    Van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75–81.
    Direct Link:
  • 4
    Takahashi Y. Memory B cells in systemic and mucosal immune response: implications for successful vaccination. Biosci Biotechnol Biochem 2007; 71: 2358–66.
  • 5
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896–908.
    Direct Link:
  • 6
    Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur J Immunol 2008; 38: 292–8.
    Direct Link:
  • 7
    Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723–32.
    Direct Link:
  • 8
    Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612–22.
    Direct Link:
  • 9
    DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 361–71.
  • 10
    Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 2008; 105: 4802–7.
  • 11
    Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5: 50–7.
    Direct Link:
  • 12
    Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257–9.
  • 13
    Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77: 2165–73.
  • 14
    Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 2001; 98: 175–9.
  • 15
    Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 2007; 104: 20878–83.
  • 16
    Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98: 205–15.
  • 17
    Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106–11.
  • 18
    Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumonia. Immunity 2005; 23: 7–18.
  • 19
    Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009; 27: 267–85.
  • 20
    Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or “memory” B cells. J Immunol 2007; 179: 13–9.
  • 21
    Scheeren FA, Nagawawa M, Weijer K, Cupedo T, Kirberg J, Legrand N, et al. T cell-independent development and induction of somatic hypermutation in human IgM+IgD+CD27+ B cells. J Exp Med 2008; 205: 2033–42.
  • 22
    Moens L, Wuyts M, Meyts I, De Boeck K, Bossuyt X. Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol 2008; 181: 5306–12.
  • 23
    Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566–75.
    Direct Link:
  • 24
    Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59: 1–15.
    Direct Link:
  • 25
    Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197: 490–502.
  • 26
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 937–41.
  • 27
    Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, et al, the Autoimmunity Centers of Excellence Immunocompetency Committee. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol 2007; 123: 235–43.
View Full Article (HTML) Get PDF (58K)